Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia:: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)

被引：136

作者：

Michallet, M ^{[1
]}

Thomas, X ^{[1
]}

Vernant, JP ^{[1
]}

Kuentz, M ^{[1
]}

Socié, G ^{[1
]}

Espérou-Bourdeau, H ^{[1
]}

Milpied, N ^{[1
]}

Blaise, D ^{[1
]}

Rio, B ^{[1
]}

Reiffers, J ^{[1
]}

Jouet, JP ^{[1
]}

Cahn, JY ^{[1
]}

Bourhis, JH ^{[1
]}

Lioure, B ^{[1
]}

Leporrier, M ^{[1
]}

Sotto, JJ ^{[1
]}

Souillet, G ^{[1
]}

Sutton, L ^{[1
]}

Bordigoni, P ^{[1
]}

Dreyfus, F ^{[1
]}

Tilly, H ^{[1
]}

Gratecos, N ^{[1
]}

Attal, M ^{[1
]}

Leprise, PY ^{[1
]}

Déméocq, F ^{[1
]}

Michel, G ^{[1
]}

Buzyn, A ^{[1
]}

Delmas-Marsalet, B ^{[1
]}

Bernaudin, F ^{[1
]}

Ifrah, N ^{[1
]}

Sadoun, A ^{[1
]}

Guyotat, D ^{[1
]}

Cavazzana-Cavo, M ^{[1
]}

Caillot, D ^{[1
]}

De Revel, T ^{[1
]}

Vannier, JP ^{[1
]}

Baruchel, A ^{[1
]}

Fegueux, N ^{[1
]}

Tanguy, ML ^{[1
]}

Thiébaut, A ^{[1
]}

Belhabri, A ^{[1
]}

Archimbaud, E ^{[1
]}

机构：

[1] Hop Edouard Herriot, Unite Greffe Cellules Souches Hematopoiet, F-69437 Lyon 3, France

来源：

BONE MARROW TRANSPLANTATION | 2000年 / 26卷 / 11期

关键词：

allogeneic; HSCT; advanced; AML;

D O I：

10.1038/sj.bmt.1702690

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

To assess the place of allogeneic hematopoietic stem cell transplantation (HSCT) in the advanced stage of acute myeloid leukemia (AML), we retrospectively analyzed 379 consecutive patients who underwent allogeneic HSCT for advanced AML. The median follow-up of the entire cohort was 7.5 years. Sixty-nine patients (18%) were transplanted with primary resistant disease. Three hundred and ten (82%) were relapsed patients, 94 (30%) of whom were in untreated relapse, 67 (22%) in refractory relapse and 149 (48%) in 2nd or 3rd complete remission at time of transplantation. The 5-year probabilities of overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM) were 22 +/- 4% 20 +/- 4%, 45 +/- 6%, respectively. In multivariate analysis, we demonstrated the favorable impact on OS, DFS and TRM of two factors over which we have no control (age <15 years, complete remission achievement) and three factors over which we have some control (female donor, acute and chronic graft-versus-host disease). The results of this study suggest that the graft-versus-leukemia effect is important in advanced AML and that new HSCT modalities are needed for some patients with this indication.

引用

页码：1157 / 1163

页数：7

共 25 条

[1]

APPELBAUM FR, 1983, BLOOD, V61, P949

[2] PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&

[3]

BLUME KG, 1993, BLOOD, V81, P2187

[4] HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP [J].

BROWN, RA ;

WOLFF, SN ;

FAY, JW ;

PINEIRO, L ;

COLLINS, RH ;

LYNCH, JP ;

STEVENS, D ;

GREER, J ;

HERZIG, RH ;

HERZIG, GP .

BLOOD, 1995, 85 (05) :1391-1395

[5] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].

Cassileth, PA ;

Harrington, DP ;

Appelbaum, FR ;

Lazarus, HM ;

Rowe, JM ;

Paietta, E ;

Willman, C ;

Hurd, DD ;

Bennett, JM ;

Blume, KG ;

Head, DR ;

Wiernik, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656

[6]

CHAMPLIN R, 1987, BLOOD, V69, P1551

[7] ALLOGENEIC MARROW TRANSPLANTATION DURING UNTREATED 1ST RELAPSE OF ACUTE MYELOID-LEUKEMIA [J].

CLIFT, RA ;

BUCKNER, CD ;

APPELBAUM, FR ;

SCHOCH, G ;

PETERSEN, FB ;

BENSINGER, WI ;

SANDERS, J ;

SULLIVAN, KM ;

STORB, R ;

SINGER, J ;

HANSEN, JA ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1723-1729

[8]

COX DR, 1972, J R STAT SOC B, V34, P187

[9]

DANA C, 1998, LEUKEMIA S1, V12, pS33

[10]

GALE RP, 1989, LANCET, V1, P1119

← 1 2 3 →